These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1410 related articles for article (PubMed ID: 27557300)

  • 1. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    Cardoso F; van't Veer LJ; Bogaerts J; Slaets L; Viale G; Delaloge S; Pierga JY; Brain E; Causeret S; DeLorenzi M; Glas AM; Golfinopoulos V; Goulioti T; Knox S; Matos E; Meulemans B; Neijenhuis PA; Nitz U; Passalacqua R; Ravdin P; Rubio IT; Saghatchian M; Smilde TJ; Sotiriou C; Stork L; Straehle C; Thomas G; Thompson AM; van der Hoeven JM; Vuylsteke P; Bernards R; Tryfonidis K; Rutgers E; Piccart M;
    N Engl J Med; 2016 Aug; 375(8):717-29. PubMed ID: 27557300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
    Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [70-Gene signature as an aid to treatment decisions in early-stage breast cancer].
    van der Hoeven JJ
    Ned Tijdschr Geneeskd; 2017; 161():D1369. PubMed ID: 28401821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
    Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Perez EA; Olson JA; Zujewski J; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin P; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Atkins JN; Berenberg JL; Sledge GW
    N Engl J Med; 2015 Nov; 373(21):2005-14. PubMed ID: 26412349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin PM; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
    N Engl J Med; 2018 Jul; 379(2):111-121. PubMed ID: 29860917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
    Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
    Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
    Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
    Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
    Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
    Wittner BS; Sgroi DC; Ryan PD; Bruinsma TJ; Glas AM; Male A; Dahiya S; Habin K; Bernards R; Haber DA; Van't Veer LJ; Ramaswamy S
    Clin Cancer Res; 2008 May; 14(10):2988-93. PubMed ID: 18483364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
    Buyse M; Loi S; van't Veer L; Viale G; Delorenzi M; Glas AM; d'Assignies MS; Bergh J; Lidereau R; Ellis P; Harris A; Bogaerts J; Therasse P; Floore A; Amakrane M; Piette F; Rutgers E; Sotiriou C; Cardoso F; Piccart MJ;
    J Natl Cancer Inst; 2006 Sep; 98(17):1183-92. PubMed ID: 16954471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.